As part of the $100 million deal, the companies will collaborate to develop more than 10 experimental drugs to treat conditions such as cardio-metabolic disorders and pain.
To expand its gene-silencing portfolio, Eli Lilly will pay $100 million upfront and buy a $100 million equity stake. Under the deal, Dicerna is eligible to receive up to $350 million and some royalties for each developed drug.
Gene-silencing technology works by targeting and turning off certain genetic material in an effort to prevent some disease-causing proteins from forming.
Johnson and Johnson has also recently invested in gene silencing firms.
More articles on pharmacy:
Drug take back day is Oct. 27: 5 things to know
Amgen cuts list price of $14K-a-year cholesterol drug nearly 60%
Trump’s plan to lower prescription drug prices: 7 takeaways
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
